Key Highlights
- First-quarter revenue reached $15.29B, surpassing the $14.94B consensus projection
- Core earnings per share of $2.58 exceeded the $2.54 analyst forecast
- Cancer treatment sales climbed 16% compared to the previous year; rare disease division increased 15%
- Annual outlook unchanged: mid-to-high single-digit revenue expansion, low double-digit core EPS advancement
- Shares dropped approximately 1% following the release, with market watchers noting strong performance was already anticipated
The British pharmaceutical giant AstraZeneca delivered robust first-quarter results on Wednesday morning, yet investors barely blinked. The company reported quarterly revenue of $15.29 billion, climbing from $13.59 billion in the same period last year and exceeding the Wall Street consensus of $14.94 billion.
Core earnings per share registered at $2.58, topping analyst expectations of $2.54. The company’s core operating profit expanded 12% to reach $4.25 billion.
Yet despite these impressive figures, AZN shares declined roughly 1% during early London market hours. According to eToro analyst Adam Vettese, the subdued response reflected that the company’s positive trajectory had already been factored into share prices.
The oncology division continues to serve as the company’s primary growth driver, representing 44% of total group revenue. The segment posted year-over-year sales growth of 16% at constant currency rates, totaling $6.8 billion.
Imfinzi, prescribed for bladder and lung cancer treatment, experienced a remarkable 30% increase to $1.7 billion. Tagrisso, targeting lung cancer patients, advanced 5% to $1.8 billion. Enhertu, designed for breast and gastric cancer treatment, skyrocketed 34% to reach $831 million.
The rare disease business unit similarly performed well, recording a 15% annual increase.
Oncology and Specialty Treatments Power Performance
Revenue from the United States expanded 10% during the quarter, while sales in China increased 2%. AstraZeneca has executed significant strategic initiatives in both territories throughout the past year, including a $50 billion U.S. manufacturing agreement and a $15 billion investment pledge in China.
The pharmaceutical company also obtained a New York Stock Exchange listing and secured exemption from U.S. tariffs through a drug pricing arrangement.
Net earnings for the first quarter improved to $3.08 billion compared to $2.92 billion in the prior-year period.
Development Portfolio and Long-Term Vision Remain Intact
Chief Executive Officer Pascal Soriot reaffirmed the organization’s ambitious goal of achieving $80 billion in annual revenue by 2030. He indicated that AstraZeneca is positioning itself for numerous product launches and continues progressing toward introducing more than 20 new therapies by the target date.
Three additional medications could potentially debut in the American market this year subject to regulatory clearance: baxdrostat for hypertension treatment, camizestrant for certain breast cancer cases, and gefurulimab for a chronic autoimmune condition.
The company’s full-year 2026 projections remained unaltered. AstraZeneca anticipates mid-to-high single-digit revenue advancement and low double-digit core earnings per share growth measured at constant currency rates.
Soriot cautioned last week that Europe faces the prospect of becoming merely a “sales office” for the pharmaceutical sector as it lags behind the United States and China. This warning provides context for AstraZeneca’s ongoing efforts to strengthen its presence in both regions.
LSEG analysts project full-year 2026 sales expansion of 7.2% and profit growth of 11.2%, closely aligned with 2025 performance.
Heading into today’s earnings announcement, AstraZeneca’s stock had remained essentially flat year-to-date. The earnings beat did little to alter that trajectory.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
